Web25 jun. 2024 · DCR was 50% (PR, 4%; SD, 46%), with a trend for higher DCR in patients with KRAS-mutant NSCLC. CDKN2A loss or mutation was not described in this study … Web30 mrt. 2024 · Also presented at ELCC 2024, an exploratory analysis of the phase II KRYSTAL-1 study of adagrasib for advanced/metastatic KRAS G12C-mutated NSCLC ( …
Durable efficacy of amivantamab in mutated NSCLC
Web27 mrt. 2024 · 226 NSCLC patients received one of the five ICI, including pembrolizumab, nivolumab, durvalumab, ipilimumab, and atezolizumab (Supplementary Fig. 3a ). … Web16 mrt. 2024 · While early clinical trials demonstrated no benefit of targeted therapy in HER2-amplified NSCLC , a separate interim analysis of the DESTINY-Lung01 study discussed above showed a 24.5 percent response rate with fam-trastuzumab deruxtecan in HER2-overexpressed, IHC 2+ or 3+, HER2 mutation-negative NSCLC, which may … cigar soft flame lighters
Lung Cancer Mutations: TP53, KRAS, EGFR, ALK, and More
Web30 mrt. 2024 · Also presented at ELCC 2024, an exploratory analysis of the phase II KRYSTAL-1 study of adagrasib for advanced/metastatic KRAS G12C-mutated NSCLC ( N Engl J Med. 2024;387:120–131) suggests a potential association between mutation allele frequency clearance (MAFC) and response (Abstract 8MO). WebRetrospective analysis of 2548 NSCLC patients who underwent EGFR mutational analysis from 2013 to 2024 using amplified refractory mutation system … Web24 nov. 2024 · Here, we investigated tumor mutational burden and mutational signatures in a clinical cohort of NSCLC. Using a 2 Mb gene panel in 39% of tumors sufficient single base substitutions were detected to describe the mutational signatures. SBS4 and SBS2/13 were detected in 33% and 14%. SBS4 appears to be more common in early stages of … dhhr hours